Osteoporos Int 20:161–162PubMed 225 Pernicova I, Middleton ET, A

Osteoporos Int 20:161–162PubMed 225. Pernicova I, Middleton ET, Aye M (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert Osteoporos Int 19:1811–1812 226. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY (2010) Treatment of osteoporosis: recognizing Talazoparib solubility dmso and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21:723–732PubMed 227. Kong YY, Yoshida H, Sarosi I et al (1999) OPGL is a key regulator

of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323PubMed 228. Baud’huin M, Lamoureux F, Duplomb L, Redini F, Heymann D (2007) RANKL, RANK, osteoprotegerin: key partners of osteoimmunology GDC-0449 molecular weight and vascular

diseases. Cell Mol Life Sci 64:2334–2350PubMed 229. Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22:435–446PubMed 230. Sobacchi C, Frattini A, Guerrini MM et al (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960–962PubMed 231. TGF-beta inhibitor Ashcroft AJ, Cruickshank SM, Croucher PI et al (2003) Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19:849–861PubMed 232. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309PubMed 233. Andrews NA (2008) Denosumab and the treatment of rheumatoid

arthritis: in an occupied field, where will a RANKL inhibitor fit in? Bone Key 5:351–356 234. Stolina M, Guo J, Faggioni R, Brown H, Senaldi G (2003) Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109:347–354PubMed 235. Miller RE, very Branstetter D, Armstrong A, Kennedy B, Jones J, Cowan L, Bussiere J, Dougall WC (2007) Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179:266–274PubMed 236. McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMed 237. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMed 238. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81PubMed 239.

Comments are closed.